| |
Glargine
n = 708 |
Detemir
n = 298 |
Glargine versus detemir |
| Characteristics |
n (%) |
n (%) |
Chi-square P value |
| Gender |
|
|
0.12 |
| Male |
397 (56) |
151 (51) |
|
| Female |
311 (44) |
147 (49) |
|
| Age, mean (SD), years |
63 (13) |
64 (13) |
<0.05 |
| Prescriber |
|
|
0.75 |
| General practitioner |
350 (49) |
144 (48) |
|
| Specialist |
358 (51) |
154 (52) |
|
| Prior anti-diabeticsa |
|
|
|
| Insulinb |
132 (19) |
92 (31) |
<0.0001 |
| OADs |
662 (94) |
271 (91) |
0.15 |
| Concomitant OAD use |
430 (61) |
201 (67) |
<0.05 |
| Comorbidityc |
|
|
|
| Any cardiovascular diseased |
123 (17) |
64 (21) |
0.13 |
| Ischemic heart disease |
98 (14) |
47 (16) |
0.43 |
| Cerebrovascular accident |
32 (5) |
15 (5) |
0.72 |
| Peripheral vascular disease |
6 (1) |
5 (2) |
0.25 |
| Congestive heart failure |
17 (2) |
10 (3) |
0.39 |
| Chronic kidney disease |
0 (0) |
1 (<0.5) |
0.12 |
| Comedicatione |
|
|
|
| Antihypertensives |
476 (67) |
210 (70) |
0.31 |
| Platelet inhibitors |
264 (37) |
110 (37) |
0.91 |
| Nitrates |
81 (11) |
37 (12) |
0.66 |
| Digoxin |
31 (4) |
15 (5) |
0.65 |
SD, standard deviation; OADs, oral anti-diabetic drugs.
aIn year prior to cohort entry date.
bOther type of insulin than index treatment.
cBased on hospitalizations in the total available history.
dIschemic heart disease or cerebrovascular accident or peripheral vascular disease.
eBased on drug dispensings in the year before cohort entry date. |
